Anaheim, Calif.—A young man came to Memorial Sloan Kettering Cancer Center (MSKCC) looking for help. He had tried multiple treatments for his acute lymphoblastic leukemia (ALL), but a bone marrow biopsy revealed his cancer had returned. So MSKCC doctors tried something new. They took his blood, extracted the T cells, and genetically engineered them to add chimeric antigen receptors (CARs), which direct the T cells to attack the patient's cancer cells.
CAR T-cell therapy is among a wave of